GeoVax Labs, Inc. reported results for the 2026 quarter showing no revenue and a reduced net loss versus the prior-year period as the company shifts focus to its lead vaccine and oncolytic programs.
Financial Highlights
| MetricCurrent quarterPrior year quarterYoY change | Revenue¹$0$852.28K(100%) | Net income²($4.43M)($5.37M)17.6% | Diluted EPS³($0.97)($8.74)88.9% |
¹ Reported as “Revenue from government contract”. ² Reported as “Net loss”. ³ Reported as “Diluted loss per common share”.
Business Highlights
- GEO‑MVA: Advancing to Phase 3 per EMA advice with a target start in late 2026 to address global orthopox vaccine supply.
- Portfolio reprioritization: Discontinued GEO‑CM04S1 to concentrate resources on GEO‑MVA and the oncolytic candidate Gedeptin.
- Gedeptin development: Completed Phase 1/2 in head and neck squamous cell carcinoma (HNSCC); planning a Phase 2 neoadjuvant combination study targeting 2027 initiation.
- Manufacturing modernization: Developing a continuous avian cell line for scalable cGMP MVA production to improve yield and responsiveness.
- Revenue & funding: No product sales this quarter; prior BARDA contract was terminated and the company is relying on equity financings and grants for funding.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.